An Operationally Seamless Phase 2/3 Randomized, Open-label, Multicenter, Active-Controlled Study to Evaluate the Safety and Efficacy of Bictegravir/Lenacapavir Versus Stable Baseline Regimen in Virologically Suppressed People With HIV-1 on Stable Complex Treatment Regimens (NCT05502341)
ARTISTRY
This trial is No longer recruiting
Registration number NCT05502341
Program & service
This trial is being run with the Infectious Diseases service, and as part of the Infectious Diseases program.
Trial phase
Phase 2
Trial participation type
This trial has been designed for the Clinical Research of a Drug.
Principal investigator
Professor James McMahon
More information
To find out more about this clinical trial, please review full details on the ANZCTR website.
View on ANZCTR